Provigil vs Vyvanse Head-to-Head Efficacy: What the Evidence Actually Shows

Why There Is No True Head-to-Head Trial

Researchers have not run a randomized controlled trial pitting modafinil directly against lisdexamfetamine in the same patient population. That absence is not an oversight. It reflects the fact that the two drugs received FDA approval for different primary indications, were developed by different sponsors at different times, and target largely separate patient groups in clinical practice.

What the literature does offer are high-quality trials for each drug in its approved indication, plus a smaller body of off-label cognition research. Comparing them requires reading across those separate datasets while resisting the urge to equate outcomes measured on different scales, in different populations, over different timeframes.

Why the Comparison Still Matters Clinically

Prescribers regularly encounter patients who could plausibly receive either agent. A college student with untreated ADHD and significant daytime sleepiness, or a shift worker whose physician suspects ADHD, genuinely faces a choice between these two drug classes. Off-label use of modafinil for ADHD symptoms is documented in the literature, and some clinicians have used lisdexamfetamine off-label for shift-work fatigue, though the evidence base for that application is thin.

How This Article Uses the Evidence

Each drug's trial data is presented on its own terms first. Then a side-by-side clinical analysis follows, based on mechanism, pharmacokinetics, effect size, duration, and safety. That structure keeps the comparison honest rather than forcing a single "winner."

Modafinil (Provigil): Mechanism and Efficacy Data

Modafinil promotes wakefulness through a mechanism distinct from classical amphetamines. It inhibits dopamine reuptake at the DAT transporter, but with far lower affinity than amphetamine-class drugs, and it also modulates norepinephrine, histamine, orexin, and serotonin pathways [1]. The net effect is sustained alertness without the pronounced cardiovascular activation or rebound fatigue seen with amphetamines.

The US Modafinil in Narcolepsy Study Group Trial

The foundational efficacy trial is the US Modafinil in Narcolepsy Study Group, published in Annals of Neurology in 1998 [1]. This multicenter, double-blind, placebo-controlled trial enrolled patients with narcolepsy and tested modafinil 200 mg and 400 mg once daily against placebo over nine weeks.

Key findings from that trial:

• Mean Epworth Sleepiness Scale (ESS) scores fell by approximately 3 to 4 points in the modafinil groups vs. Less than 1 point with placebo (P<0.001).
• Maintenance of Wakefulness Test (MWT) latency improved significantly in both active arms.
• Modafinil produced these wakefulness gains without the peripheral sympathomimetic side effects typical of amphetamine-class agents at therapeutic doses.

The investigators concluded that modafinil at both doses was effective and well tolerated, with the 200 mg dose offering a favorable benefit-to-side-effect ratio for most patients.

Off-Label Use for ADHD and Cognitive Enhancement

A 2003 meta-analysis by Turner et al. And subsequent placebo-controlled trials showed that modafinil at 200 to 400 mg improved sustained attention, working memory, and executive function in healthy adults under sleep-deprived conditions [2]. Effect sizes in those studies were modest (Cohen's d approximately 0.3 to 0.5) but consistent across multiple neuropsychological batteries.

For ADHD specifically, a Cochrane-style review by Kahbazi et al. (2009) found modafinil superior to placebo on ADHD rating scales in children and adolescents, though the FDA declined to approve modafinil for ADHD in pediatric patients following a serious skin reaction signal in trials [3]. That decision still shapes prescribing today.

Dosing and Duration

Standard dosing for narcolepsy and shift-work disorder is 200 mg taken once in the morning or 1 hour before a shift. Some patients need 400 mg for adequate wakefulness. The drug reaches peak plasma concentration in 2 to 4 hours and has a half-life of 12 to 15 hours, supporting once-daily dosing [4].

Lisdexamfetamine (Vyvanse): Mechanism and Efficacy Data

Lisdexamfetamine is an inactive prodrug. After oral ingestion, enzymatic cleavage in red blood cells releases d-amphetamine, which then reverses the dopamine and norepinephrine transporters (DAT and NET), flooding synapses with both catecholamines [5]. This mechanism produces a strong, sustained stimulant effect with a smoother pharmacokinetic curve than immediate-release amphetamine salts, largely because the prodrug conversion rate-limits the release of active drug.

Wigal et al. (2017): Duration of Action in ADHD

The Wigal et al. Trial published in the Journal of Attention Disorders in 2017 is one of the clearest demonstrations of lisdexamfetamine's duration advantage over shorter-acting comparators [6]. The study assessed symptom control throughout the day using ADHD rating scales and analog classroom protocols.

Key findings:

• Symptom control was maintained consistently across the 12 to 13 hour observation window, with the drug continuing to outperform placebo on attention and behavioral measures into the early evening hours.
• The smooth, extended release profile reduced the "rebound" effect (increased irritability or hyperactivity as the drug wears off) that is common with immediate-release amphetamine salts.
• Adverse events included decreased appetite, insomnia, and increased heart rate, consistent with the amphetamine class profile.

The clinical message from Wigal et al. Is that lisdexamfetamine's prodrug design translates into clinically meaningful duration, covering the full academic or work day from a single morning dose.

Broader ADHD Efficacy: The SPD489 Development Program

The lisdexamfetamine development program included multiple Phase III trials. A key adult ADHD trial (Adler et al., J Clin Psychiatry 2008, N=420) showed a mean ADHD Rating Scale IV (ADHD-RS-IV) total score reduction of 16.2 points from baseline with lisdexamfetamine 70 mg vs. 4.0 points with placebo (P<0.001) [7]. Response rates (50% or greater symptom reduction) reached 59.8% with lisdexamfetamine vs. 21.6% with placebo.

These are large effect sizes by psychiatric trial standards (Cohen's d approximately 0.9 to 1.0 in the adult ADHD literature for lisdexamfetamine).

Binge-Eating Disorder Approval

Lisdexamfetamine received FDA approval for moderate-to-severe binge-eating disorder in 2015, making it the first medication approved for that indication. The McElroy et al. Trial (N=255, 2015) reported a 47.6% reduction in binge-eating days per week with lisdexamfetamine 50 to 70 mg vs. 19.8% with placebo [8]. This approval expanded the drug's clinical profile beyond ADHD.

Direct Comparison: Mechanism, Pharmacokinetics, and Effect Size

The table below synthesizes the available data across the two drugs. No single head-to-head study produced these numbers together. They are drawn from the primary trials cited above and from FDA prescribing information.

| Feature | Modafinil (Provigil) | Lisdexamfetamine (Vyvanse) | |---|---|---| | Drug class | Eugeroic (wakefulness-promoting) | Amphetamine prodrug (CNS stimulant) | | Primary mechanism | DAT inhibition, orexin/histamine modulation | DAT/NET reversal via d-amphetamine | | FDA-approved indications | Narcolepsy, OSA daytime sleepiness, shift-work disorder | ADHD (≥6 y), binge-eating disorder | | Onset of effect | 30 to 60 min | 60 to 120 min | | Duration | 12 to 15 h | 12 to 14 h | | Peak plasma (Tmax) | 2 to 4 h | 3.8 h (d-amphetamine) | | DEA Schedule | IV | II | | Typical adult dose | 200 to 400 mg/day | 30 to 70 mg/day | | Effect size (primary indication) | ESS reduction 3 to 4 pts vs placebo [1] | ADHD-RS-IV reduction ~12 pts vs placebo [7] | | Cardiovascular activation | Mild | Moderate to pronounced | | Abuse liability | Low to moderate | Moderate to high | | Controlled-substance restrictions | Less restrictive | More restrictive (no refills, written Rx) |

What the Mechanisms Predict About Cognitive Effects

Modafinil's weaker catecholamine action predicts a milder cognitive profile: improvements in vigilance, sustained attention, and reaction time, but smaller gains in working memory and executive function compared to amphetamine-class drugs. That prediction is broadly supported by the healthy-volunteer literature [2].

Lisdexamfetamine's full dopamine/norepinephrine reversal predicts larger effect sizes on ADHD-specific cognitive deficits (working memory, inhibitory control) in individuals with true dopaminergic dysregulation. In neurotypical adults, the incremental benefit over modafinil likely shrinks considerably and comes at a higher side-effect cost.

Duration and Quality of Effect

Both drugs cover a 12 to 14 hour window from a single morning dose. The quality of that coverage differs. Modafinil tends to produce steady, calm wakefulness without pronounced mood elevation. Lisdexamfetamine, through sustained d-amphetamine release, may produce more noticeable mood brightening and motivational enhancement, but also more pronounced appetite suppression and heart rate increases.

Approved Indications vs. Off-Label Use

This is the most clinically significant dividing line between the two drugs.

When Modafinil Is the Indicated Choice

Modafinil has a strong evidence base and FDA approval for:

• Narcolepsy with or without cataplexy
• Residual daytime sleepiness in patients with obstructive sleep apnea already on PAP therapy
• Shift-work sleep disorder in people with irregular work schedules

For a patient whose primary complaint is excessive daytime sleepiness from a documented sleep disorder, modafinil is the first-line pharmacologic option in most guidelines. The American Academy of Sleep Medicine (AASM) clinical practice guideline states: "We recommend that clinicians use modafinil or armodafinil for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy" [9].

When Lisdexamfetamine Is the Indicated Choice

Lisdexamfetamine is the indicated agent when the diagnosis is ADHD (inattentive, hyperactive, or combined presentation) or moderate-to-severe binge-eating disorder. The 2023 American Academy of Pediatrics ADHD guideline and the American Academy of Child and Adolescent Psychiatry (AACAP) both list amphetamine-class stimulants among first-line pharmacologic treatments alongside methylphenidate-class agents [10].

For an adult with ADHD who has not responded to methylphenidate, lisdexamfetamine is a reasonable and guideline-supported next step.

Off-Label Cognition Use: What the Evidence Supports

Both drugs are used off-label for cognitive enhancement in healthy individuals. A 2015 systematic review by Battleday and Brem in European Neuropsychopharmacology analyzed 24 studies and found modafinil improved performance on complex tasks requiring planning, decision-making, and sustained attention, with a cleaner side-effect profile than amphetamines in non-sleep-deprived healthy adults [11]. Lisdexamfetamine has not been studied as systematically in that context, and its Schedule II status makes clinical trials in healthy volunteers more difficult to conduct.

Safety and Tolerability: Where the Drugs Diverge Most

The safety profiles of these two drugs differ more than their efficacy profiles do. That difference often determines which drug is appropriate for a given patient.

Cardiovascular Effects

Modafinil produces modest increases in heart rate (average 3 to 4 bpm) and blood pressure. Lisdexamfetamine produces more pronounced effects, with mean systolic blood pressure increases of 3 to 4 mmHg and heart rate increases of 3 to 7 bpm reported in clinical trials, and occasional larger excursions in individual patients [5]. For patients with hypertension, structural heart disease, or arrhythmia, this distinction matters.

The FDA label for lisdexamfetamine carries a warning against use in patients with serious structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm problems. Modafinil's label contains no equivalent black-box cardiovascular warning.

Psychiatric Side Effects

Both drugs can worsen anxiety and insomnia. Lisdexamfetamine carries a higher risk of triggering psychosis or mania in susceptible individuals, consistent with the broader amphetamine class literature. Modafinil has been associated with anxiety and mood changes, but the incidence is lower than with amphetamines.

Abuse and Dependence

Lisdexamfetamine's Schedule II classification reflects significant misuse potential, though its prodrug design does partially blunt the sharp onset that drives amphetamine misuse. Modafinil's Schedule IV status reflects a lower but real misuse potential. A 2012 pharmacology review estimated modafinil's reinforcing effects at roughly one-tenth of amphetamine's in animal models, though human data on this are limited [12].

Skin Reactions and Rare Serious Events

Modafinil carries FDA warnings for serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These are rare but serious. This warning contributed to the FDA's 2006 rejection of modafinil for pediatric ADHD. Patients should stop the drug immediately at the first sign of a rash.

Which Patients Benefit Most From Each Drug

The clinical decision between these two agents is diagnosis-driven in most cases, not a pure efficacy comparison.

Patient Profiles for Modafinil

• Confirmed narcolepsy or idiopathic hypersomnia
• Residual sleepiness on PAP-treated OSA
• Rotating or night-shift workers
• Patients who cannot tolerate amphetamine-class stimulants due to cardiovascular comorbidity or anxiety
• Patients for whom Schedule II prescribing restrictions are a practical barrier

Patient Profiles for Lisdexamfetamine

• Adults and children (≥6 years) with confirmed ADHD diagnosis
• ADHD patients who require coverage into the evening (homework, after-school activities)
• Adults with comorbid binge-eating disorder and ADHD
• Patients who have failed or partially responded to methylphenidate-class agents
• Individuals where working memory and executive function are the primary cognitive targets

Can Modafinil Be Used for ADHD, and Can Vyvanse Be Used for Sleep Disorders?

Modafinil for ADHD

Off-label use of modafinil for ADHD is practiced by some clinicians, particularly in adult patients. A meta-analysis by Castells et al. (Cochrane Database, 2011) found modafinil superior to placebo on ADHD symptom scales in adults, with a standardized mean difference of 0.47 [3]. That is a moderate effect size. The absence of FDA approval reflects the pediatric skin reaction signal, not a finding of inefficacy in adults.

Modafinil should be considered a second- or third-line option for ADHD, not a first choice. The American Academy of Pediatrics does not include it in their primary ADHD treatment algorithm.

Lisdexamfetamine for Sleep Disorders

No high-quality evidence supports lisdexamfetamine as a primary treatment for narcolepsy or shift-work disorder. Amphetamines have historically been used for narcolepsy, but their cardiovascular burden and abuse liability led to modafinil and armodafinil replacing them as preferred wakefulness-promoting agents. Prescribing lisdexamfetamine for shift-work sleep disorder would be an off-label use with a weaker evidence base than modafinil in that indication.

Practical Prescribing Considerations

Starting Doses and Titration

Modafinil is typically started at 200 mg once daily in the morning. Titration to 400 mg is possible but does not always produce proportionally greater efficacy. The prescribing information recommends lower starting doses in patients with hepatic impairment.

Lisdexamfetamine is started at 30 mg once daily in adults, with weekly titration by 10 to 20 mg increments to a maximum of 70 mg/day based on response and tolerability.

Drug Interactions

Modafinil is a moderate inducer of CYP3A4 and may reduce plasma concentrations of hormonal contraceptives, cyclosporine, and certain antiretrovirals. Women taking oral contraceptives while on modafinil should use a barrier method during treatment and for one month after stopping the drug.

Lisdexamfetamine interacts with monoamine oxidase inhibitors (MAOIs), which are contraindicated within 14 days of amphetamine use. It also has clinically relevant interactions with acidifying agents (which increase renal clearance of amphetamine) and alkalinizing agents (which decrease clearance and can raise plasma levels).

Cost and Insurance Coverage

Generic modafinil (200 mg, 30 tablets) is available for approximately $20, $60 at major pharmacies through discount programs. Branded Provigil costs significantly more. Vyvanse does not have a fully generic equivalent as of early 2025, with branded 30-day supplies running $300, $400 out of pocket, though manufacturer savings cards and insurance coverage vary widely.

Key Takeaways for Clinicians and Patients

Both modafinil and lisdexamfetamine improve alertness and attention, but they do so through different mechanisms, in different clinical populations, with different risk profiles.

Modafinil is the preferred agent for wakefulness disorders and carries a cleaner cardiovascular and abuse-risk profile. Lisdexamfetamine delivers larger effect sizes for ADHD-specific cognitive deficits and has the stronger evidence base for that indication.

The question "Is Provigil better than Vyvanse?" does not have a single answer. For a shift worker with excessive sleepiness, modafinil 200 mg is better supported by evidence and regulatory approval. For an adult with ADHD who needs 13-hour symptom control, lisdexamfetamine 50 to 70 mg is better supported. No trial has tested both drugs head-to-head in either population.

Before prescribing either agent, clinicians should confirm the working diagnosis, assess cardiovascular and psychiatric comorbidities, review the patient's controlled-substance history, and align the drug choice to the FDA-approved indication whenever possible.